| Ytd | -54.68% | |
| 1y | 29.65% |
| Open | 13.77 | Prev Close | 13.74 | Low | 13.55 | High | 14.03 | Mkt Cap | 341.84M |
| Vol | 105.43K | Avg Vol | 182.41K | EPS | -13.80 | P/E | -1.01 | Forward P/E | -0.73 |
| Beta | -0.48 | Short Ratio | 6.15 | Inst. Own | 58.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-15 | 50-d Avg | 13.41 | 200-d Avg | 20.48 | 1yr Est | 1.00 |
LYEL News
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits o
B. Riley Securities analyst Yuan Zhi initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with
Lyell Immunopharma, Inc. (NASDAQ: LYEL - Get Free Report) has received an average rating of "Moderat
The average of price targets set by Wall Street analysts indicates a potential upside of 176% in Lye
SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYE
Lyell Immunopharma (LYLE) offers asymmetric upside, with ronde-cel showing best-in-class durability
More than 100 patients treated with ronde-cel in 2L and 3L+ LBCL, with a manufacturing success rate
Lyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2
on Lyell Immunopharma Inc. (NASDAQ: LYEL) stock is up on Monday as the company is providing an updat
SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYE
SOUTH SAN FRANCISCO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYE
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure mi
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYE
Lyell Immunopharma NASDAQ: LYEL President and CEO Lynn Seely outlined the company's clinical develop
Lyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript
Lyell Immunopharma, Inc. (LYEL) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conferenc
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure mi
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL
PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line se
Lyell Immunopharma, Inc. (NASDAQ: LYEL - Get Free Report) was the recipient of a significant increas
Wall Street analysts changed outlook on top stocks. See rating changes on NKE, SMPL, WSR, NTNX, and
On Wednesday, 807 companies reached new 52-week lows.